
Roland Clayton Merchant, MD, MPH ScD
About Me
Roland Clayton (Clay) Merchant, MD, MPH, ScD is an Adjunct Professor in the Department of Emergency Medicine at the Mount Sinai Hospital. His research interests include HIV/HCV/STD, substance use and health literacy screening and interventions; blood/body fluid exposure management; and program implementation.
Dr. Merchant’s research concerns the intersection of emergency medicine, infectious diseases, and public health. He has been continuously supported as a principal investigator by the National Institutes of Health since 2004, and also has received funding from the Centers for Disease Control and Prevention and private foundations. Prior to joining the faculty at the Icahn School of Medicine at Mount Sinai, he was faculty at Brigham and Women’s Hospital/Harvard Medical School for three years, and faculty at the Alpert Medical School and the School of Public Health of Brown University for almost seventeen years. He mentors junior investigators from multiple levels of training on research methodology: undergraduate students, medical students, residents, fellows, and junior faculty.
ADDITIONAL TRAINING
Implementation Science Certificate Program, University of California San Francisco
Doctor of Science (Epidemiology), Harvard School of Public Health
Master of Public Health (Quantitative Methods), Harvard School of Public Health
Research Fellowship, The Miriam Hospital/Rhode Island Hospital/Brown University
Language
English
Position
ADJUNCT PROFESSOR | Emergency Medicine
Industry Relationships
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device, biotechnology companies, and other outside entities to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their outside financial relationships.
Dr. Merchant did not report having any of the following types of financial relationships with industry and other outside entities during 2024 and/or 2025: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Mount Sinai’s faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.